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The hepatic peptide hormone hepcidin regulates dietary iron absorption, plasma iron concentrations, and tissue iron distribution.
Hepcidin acts by causing the degradation of its receptor, the cellular iron exporter ferroportin. The loss of ferroportin decreases
iron ﬂow into plasma from absorptive enterocytes, from macrophages that recycle the iron of senescent erythrocytes, and from
hepatocytesthatstoreiron,therebyloweringplasmaironconcentrations.Malfunctionsofthehepcidin-ferroportinaxiscontribute
to the pathogenesis of diﬀerent anemias. Deﬁcient production of hepcidin causes systemic iron overload in iron-loading anemias
suchasbeta-thalassemia;whereashepcidinexcesscontributestothedevelopmentofanemiaininﬂammatorydisordersandchronic
kidney disease, and may cause erythropoietin resistance. The diagnosis of diﬀerent forms of anemia will be facilitated by improved
hepcidin assays, and the treatment will be enhanced by the development of hepcidin agonists and antagonists.
1. Hepcidin-FerroportinInteraction
Regulates IronHomeostasis
Hepcidin is a small peptide hormone secreted by hepato-
cytes, circulating in blood plasma and excreted in urine
[1]. Like other peptide hormones, hepcidin is synthesized
initially as a larger 84-amino acid preprohepcidin then
processed in hepatocytes by the signal peptidase to 60-amino
acid prohepcidin that lacks iron-regulatory activity [2]. Prior
to secretion, prohormone convertases cleave prohepcidin at
a polybasic motif to generate the mature bioactive 25-amino
acid hepcidin [3]. Other cell types including macrophages
and adipocytes also contain hepcidin mRNA but their local
and systemic contribution to the production of bioactive
hepcidin has not been established with certainty. Hepcidin
plays an essential role in maintaining iron homeostasis, and
the dysregulation of its production underlies many iron dis-
orders.Chronicexcessofhepcidincausesiron-restrictedane-
mia [4], whereas hepcidin deﬁciency results in iron overload
with iron deposition in the liver and other parenchyma [5].
Hepcidin acts by regulating the cellular concentration of
its receptor, ferroportin. Ferroportin is the sole known cel-
lular iron exporter and is essential for iron homeostasis [6].
Thismultispanningmembraneproteinisexpressedintissues
which transport large amounts of iron (Figure 1): duodenal
enterocytes which absorb dietary iron, macrophages of the
spleen and liver which recycle iron from old erythrocytes,
hepatocytes which store and release iron according to body
needs, and placental trophoblast which transports iron from
maternal to fetal circulation [7–9].
When ferroportin is located in the cell membrane it
allows eﬄux of iron from the cells into plasma. Hepcidin
binding to the extracellular face of ferroportin triggers inter-
nalization and degradation of the ligand-receptor complex
[10]. Removal of ferroportin from the membrane stops
cellular iron export leading to decreased supply of iron into
plasma (Figure 1). Without the constant iron inﬂux, the
plasma iron pool is rapidly depleted by the iron-consuming
cells, most prominently erythroid precursors. In mice, a
single injection of synthetic hepcidin caused a rapid drop
in serum iron [11], and this lasted for 2 days, presumably
until suﬃcient amount of ferroportin was resynthesized.
Decreased ferroportin concentration in cell membranes, as
seen during chronic overproduction of hepcidin, can lead
to iron-restricted erythropoiesis. Interestingly, ferroportin
is also expressed in erythroid precursor cells [12], but its2 Advances in Hematology
physiological role or the eﬀect of hepcidin on developing
erythrocytes remains to be determined.
2. Regulation of Hepcidin
Hepcidin is homeostatically regulated by iron and erythro-
poietic activity. Increased plasma and stored iron stimulate
hepcidin production, which in turn blocks dietary iron
absorption and further iron loading (Figure 1). Hepcidin
i ss u p p r e s s e di ni r o nd e ﬁ c i e n c y[ 13], allowing increased
absorption of dietary iron and replenishment of iron stores.
The feedback loop between iron and hepcidin ensures the
stability of plasma iron concentrations.
As would be expected for the iron-regulatory hormone,
hepcidin production is also regulated by the process which
consumes most iron, erythropoiesis [14]. Increased erythro-
poietic activity suppresses hepcidin production which allows
thereleaseofstoredironfrommacrophagesandhepatocytes,
and increased iron absorption, all resulting in greater supply
of iron for hemoglobin synthesis.
Hepcidin production is also pathologically increased in
inﬂammation and infection [15]. Resultant hypoferremia
mayrepresentahostdefensestrategytolimitironavailability
to microorganisms, but can also lead to iron dysregulation
and iron-restricted anemia in inﬂammatory diseases.
3.MolecularMechanismsof
HepcidinRegulation
3.1. Iron. Hepcidin is likely regulated by both circulating
iron-transferrin and intracellular iron stores. Although the
respective mechanisms of sensing extracellular and intra-
cellular iron are not well understood, they both appear to
utilize the bone morphogenetic protein (BMP) pathway to
alter hepcidin expression. Several BMPs have been shown
to increase hepcidin production in vitro and in vivo [16],
but BMP6 has recently emerged as the principal endogenous
BMP regulating hepcidin. BMP6 knockout mice develop
severe iron overload but no other signiﬁcant abnormalities
[17, 18].
In other biological settings, BMP signaling is known to
be modulated by coreceptors and antagonists. Hemojuvelin
(HJV), a GPI-linked membrane protein, appears to be the
co-receptor specialized for iron regulation [19]. The soluble
form of hemojuvelin acts as an antagonist, probably by
binding BMPs, but the biological role of this interaction has
not been documented yet [20]. HJV mutations in humans or
mice result in severe iron overload similar to that caused by
ablation of hepcidin, without any other apparent problems
[21]. Additional molecules, including a protease TMPRSS6
[22] and a large multifunctional transmembrane protein
neogenin [23], were shown to interact with HJV and modify
its cell-surface expression. Whether these molecules or their
interaction with HJV is modulated by iron or other signals
remains to be determined.
The mechanism by which intracellular iron regulates
hepcidin expression is still unclear. However, expression of
BMP6 mRNA was recently shown to increase with iron
loading in mice, raising the possibility that BMP6 is a
signal reﬂecting iron stores [24]. Hepcidin regulation by
extracellular iron is better understood, and a tentative model
is emerging but needs further experimental support. Sensing
of iron-transferrin concentrations apparently depends on
transferrin receptor 2 (TfR2) and HFE, two molecules which
are mutated in the adult form of hereditary hemochromato-
sis. TfR2 is a homolog of TfR1, but is primarily expressed
in the liver, the site of hepcidin expression. Binding of
iron-transferrin to TfR2 stabilizes the protein [25], which
results in elevated ERK1/2 and Smad1/5/8 signaling [26].
HFE, a protein similar to MHC I type molecules, appears
to function as a shuttle between TfR1 and TfR2 depending
on iron-transferrin concentrations [27]. Because the binding
sites of HFE and iron-transferrin on TfR1 overlap, higher
iron-transferrin concentrations displace HFE from TfR1
allowing HFE to associate with TfR2, which presumably
potentiates signaling pathways downstream of TfR2. HFE
andTfR2,however,donotappeartoberequiredforhepcidin
regulation by iron stores, as mice and humans with HFE and
TfR2 mutations are still capable of decreasing hepcidin levels
after iron depletion [28].
3.2. Erythropoiesis. Increased erythropoietic activity is a
potent suppressor of hepcidin production. A single injection
of erythropoietin in humans caused a dramatic decrease in
serum hepcidin within 24 hours [29], and a mouse model
showed a dose-dependent decrease in hepcidin mRNA after
erythropoietin administration [30]. Epo by itself does not
appeartobeadirectregulatorofhepcidinexpressionbecause
pretreatment of mice with carboplatin, a cytotoxic inhibitor
of erythropoiesis, completely abrogated the eﬀect of Epo on
hepcidin [14]. Similarly, mouse models of anemias caused
by bleeding or hemolysis showed that hepcidin suppression
depended on intact erythropoietic activity [14, 31].
How erythropoiesis aﬀects hepcidin production is not
clear, but the mediators could include the production of
soluble factors by the erythroid precursors in the bone
marrow, decreased circulating or stored iron, and hypoxia.
Two proteins produced by erythroid precursors, growth
diﬀerentiation factor 15 (GDF15) and twisted gastrulation
protein (TWSG1), have been proposed to mediate hepcidin
suppression in anemias with ineﬀective erythropoiesis [32,
33]. GDF15, a member of the TGF-β superfamily, and
TWSG1, a BMP-binding protein, are both produced by
developing erythroblasts. The two proteins were shown to
suppress hepcidin mRNA in vitro [32, 33]. Very high levels
of GDF15 were detected in β-thalassemia and congenital
dyserythropoietic anemia type I, and elevated Twsg1 expres-
sion was found in a mouse model of thalassemia. However,
physiologic hepcidin suppression in response to bleeding or
to anemias with eﬀective erythropoiesis is likely mediated by
other mechanisms. Whatever the signal, erythroid activity
appears to suppress hepcidin, at least in part, by modulating
the BMP pathway. Erythropoietin administration in mice,
which caused the expected decrease in hepcidin levels, was
also found to reduce Smad signaling [30].
The physiological relevance of hepcidin regulation by
hypoxia is still uncertain. Alterations of the HIF pathway inAdvances in Hematology 3
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Figure 1: Hepcidin-ferroportin interaction determines the ﬂow of iron into plasma. Hepcidin concentration is in turn regulated by iron,
erythropoietic activity, and inﬂammation.
vivo can aﬀect hepcidin expression [34] but whether HIF
regulates hepcidin transcription directly or mostly indirectly
is still unresolved. It is possible that the main eﬀect of
hypoxia on iron homeostasis is to increase erythropoietin
production in the kidney, which would lead to proliferation
of erythroblasts and suppression of hepcidin by putative
erythroid factors.
3.3. Inﬂammation. Hepcidin synthesis is rapidly increased
by infection and inﬂammation, causing retention of iron
in macrophages and decreased iron absorption [15]. The
resulting hypoferremia is presumably a component of innate
immune responses that deprive invading microbes of iron
and other essential nutrients. Serum hepcidin was found
to be greatly increased in patients with inﬂammation
deﬁned as CRP > 10mg/dL, patients with sepsis, burns,
inﬂammatory bowel disease, and multiple myeloma [13, 35–
37]. Of inﬂammatory mediators regulating hepcidin, IL-6
was shown to be a prominent inducer in vitro and in vivo,
and it stimulates hepcidin transcription through a STAT-3
dependent mechanism [38, 39]. Other cytokines such as IL-
1 may also directly regulate hepcidin production, at least
in mice, as IL-6 knockout mice with chronic inﬂammation
increased hepcidin mRNA similarly to wild-type mice [40].
Direct regulation of hepcidin synthesis in myeloid cells by
microbial molecules acting through toll-like receptors has
also been proposed [41] but it is not clear how much this
mechanism contributes to hepcidin production locally or
systemically, and whether it also applies to hepatocytes.
4. The Role of HepcidininAnemias
Hepcidin expression is the result of the interplay between
multiple stimuli, including iron, inﬂammation, and erythro-
poiesis. Accordingly, hepcidin concentrations in diﬀerent
forms of anemia vary widely, and may have diagnostic
potential in diﬀerentiating between the various types of
anemia. Furthermore, in cases where hepcidin is a causative
factor in anemia, hepcidin-targeted therapies may improve
treatment options for the patients.
4.1. Iron Deﬁciency Anemia (IDA). In pure iron deﬁciency
anemia, serum and urinary hepcidin concentrations are
greatly decreased and are frequently undetectable by cur-
rentlyavailableassays[13].Thelowexpressionispresumably
due to the lack of transcriptional stimulation by iron as well
as active suppression by erythroid factors. Hepcidin appears
to be a sensitive indicator of iron deﬁciency even in the
absence of anemia. Decreased hepcidin, together with low
transferrin saturation and serum ferritin, is observed prior
to a detectable decrease in Hb or Hct ([13], E. Nemeth
unpublished). Hepcidin measurements could improve the
screening of blood donors, in whom deferral is currently
based on low Hct or Hb levels, the relatively late sequelae
of iron deﬁciency. Identifying donors who are already iron-
deﬁcient prior to the blood donation should reduce the fre-
quency of frank iron deﬁciency and anemia in blood donors.
Hepcidin is readily detectable in urine [13] and thus may
be an excellent candidate for the development of a simple4 Advances in Hematology
ﬁeld test for iron deﬁciency. Apart from the possible use
for easy screening of infants and small children, a ﬁeld-
friendly test would be particularly useful in areas which
lack access to clinical laboratories. Accurate detection of
iron deﬁciency has become an important issue in endemic
malarialregions.“ThePembatrial,”arandomizedcontrolled
trial in Zanzibar [42] which evaluated the impact of iron,
folic acid, and zinc supplementation on morbidity and
mortalityinyoungchildren,foundanincreasedriskofsevere
illness and death in children supplemented with iron/folic
acid. Furthermore, the risk appeared to be restricted to iron-
replete children. Thus, a simple, quick hepcidin test would
helpdistinguishbetweeniron-deﬁcient/anemicchildrenwho
can beneﬁt from iron supplementation, and iron-replete or
already infected children in whom iron supplementation
might be harmful.
4.2. Iron-Refractory Iron Deﬁciency Anemia (IRIDA). Iron-
refractory iron deﬁciency anemia is a hereditary
hypochromic, microcytic anemia, refractory to treatment
with oral iron, and only partially responsive to parenteral
iron. The molecular basis of the disease was only recently
described.IRIDAiscausedbyincreasedhepcidinproduction
due to mutations in the hepcidin suppressor, TMPRSS6
also called matriptase-2 [43, 44]. The disease is thus a
phenotypic opposite of juvenile hemochromatosis caused
by disruptive hepcidin mutations. TMPRSS6 is a membrane
protease which was reported to act by cleaving membrane-
associated HJV [22], which presumably results in decreased
BMP pathway activity. When TMPRSS6 is mutated,
hepcidin expression is increased, chronically inhibiting
iron absorption and resulting in the development of iron
deﬁciency anemia. How TMPRSS6 expression and activity
are regulated in relation to iron homeostasis still remains to
be determined.
Interestingly, TMPRSS6 locus is proving to be highly
polymorphic. If some common polymorphisms confer
changes in TMPRSS6 expression or activity, this could
in turn aﬀect hepcidin expression and the control of
iron metabolism. Recently, genome-wide association stud-
ies identiﬁed association between certain TMPRSS6 vari-
ants and serum iron, transferrin saturation, MCV and
hemoglobin levels [45, 46]. These ﬁndings suggest that even
subtle variants in hepcidin regulators have an inﬂuence
on iron status, erythropoiesis, and associated disorders in
the general population. Improved deﬁnition of genetic risk
factors for iron deﬁciency or iron overload could help avoid
unnecessary burdens associated with chronic treatment.
4.3. Iron-Refractory Anemia Associated with Hepcidin-
producing Tumors. Another rare form of iron-refractory
iron deﬁciency anemia is associated with hepatic adenomas.
Originally reported in the setting of type 1a glycogen storage
disease, patients had large hepatic adenomas associated
with moderate to severe unremitting microcytic anemia
and hypoferremia, unresponsive to oral iron and only
partially responsive to parenteral iron [47]. The anemia
and hypoferremia rapidly resolved after tumor resection.
A sample of tumor tissue overexpressed hepcidin mRNA
which was suppressed in the surrounding liver, suggesting
autonomous production of hepcidin by the tumor. A patient
with a similar presentation in the setting of a large hepatic
adenoma but no history of glycogen disorder was recently
reported [48].
4.4. Iron-Loading Anemias. In iron-loading anemias, such
as β-thalassemia and congenital dyserythropoietic anemias,
urinary and serum hepcidin are severely decreased in the
absence of transfusions [49–51]. The low hepcidin in turn
allows excessive iron absorption and development of sys-
temic iron overload, similar to hereditary hemochromatosis.
The signal causing hepcidin suppression in iron-loading
anemias appears to be generated by high erythropoietic
activity and outweighs the eﬀects of the resulting iron
overload on hepcidin regulation. As mentioned earlier,
GDF15 and TWSG1 are two erythroid factors that may
contribute to hepcidin suppression in syndromes with
ineﬀective erythropoiesis [32, 33].
Hepcidin diagnostics may be useful for iron-loading
anemias to identify the patients at higher risk of iron toxicity
due to severely decreased hepcidin levels. Moreover, future
hepcidin agonists may be suﬃcient to prevent the life-
threatening iron overload in these patients. The ﬁrst promis-
ing evidence of the beneﬁcial eﬀect of hepcidin comes from
the th3/+ mouse model of β-thalassemia in which moderate
transgenic expression of hepcidin resulted in lower spleen
and liver iron content, decreased ineﬃcient erythropoiesis in
the spleen, lower spleen weight, and even improvement of
hematological parameters (Gardenghi et al., submitted).
In chronically transfused patients, hepcidin concentra-
tions are much higher than in nontransfused patients, pre-
sumably due to both increased iron load and the alleviation
of ineﬀective erythropoiesis [49, 51]. Interestingly, Origa
et al. [51] showed that nontransfused patients have liver
iron concentrations similar to those of regularly transfused
thalassemiamajorpatients.However,becauseofthediﬀerent
hepcidin levels, the cellular distribution of iron in the liver
diﬀered in these two groups. In nontransfused thalassemia,
iron was deposited in hepatocytes, whereas higher hepcidin
levels in transfused patients resulted in macrophage iron
loading. As a consequence of this diﬀerence in cellular
iron distribution, serum ferritin levels were much lower in
nontransfused patients, and did not adequately reﬂect the
patients’ liver iron load. Considering that high hepcidin
shiftsiron distribution tomacrophagesanddecreasesintesti-
nalironabsorption,itispossiblethathepcidinagonistscould
be useful even in transfused thalassemia patients. Trapping
iron in macrophages where it is less toxic may postpone iron
deposition and consequent damage in the parenchyma, but
this remains to be investigated.
4.5. Anemia of Inﬂammation. Anemia of inﬂammation (AI)
develops in the setting of many infections and inﬂammatory
disorders, and some malignancies [52]. Elevated hepcidin
is believed to be an important mediator of AI but whether
hepcidin is a necessary factor in the AI pathogenesis has
not yet been established with certainty. IRIDA and mouse
models overexpressing hepcidin demonstrate that elevatedAdvances in Hematology 5
hepcidin is suﬃcient to cause hypoferremia and anemia [4].
Moderate overproduction of hepcidin in transgenic mice or
in mice bearing hepcidin-producing tumors caused an iron-
restricted anemia [4, 53]. Transgenic mice also had blunted
erythropoietic response to EPO, another characteristic of AI.
In humans, elevated hepcidin was observed in a variety
of inﬂammatory disorders including rheumatologic diseases,
inﬂammatory bowel disease, infections, multiple myeloma,
and critical illness [13, 35–37, 54, 55]. The AI phenotype
presumably develops from hepcidin-mediated inhibition of
iron recycling and absorption. Decreased ﬂow of iron into
plasma results in hypoferremia, and because most of the
iron in plasma is destined for the bone marrow, lower iron
availability hinders hemoglobin synthesis and erythrocyte
production.
Detecting elevated hepcidin in the presence of hypo-
ferremia and anemia could help distinguish AI from IDA.
However, mixed anemia is common, for example, in cases
of chronic inﬂammatory illness with coexisting bleeding
or malnutrition. In these conditions, the inﬂammation-
mediated increase in hepcidin would be opposed by the
eﬀects of iron deﬁciency. Even without blood loss or
malnutrition, when inﬂammation lasts for years, true iron
deﬁciency may also develop because of the inhibition
of intestinal iron absorption by hepcidin. The ability of
hepcidin measurements to distinguish the contribution of
iron deﬁciency and inﬂammation in these conditions will
have to be carefully evaluated. It is possible that even
“normal” levels of hepcidin in AI or mixed anemia are
inappropriate and perpetuate iron restriction. Obesity, itself
a chronic inﬂammatory condition, was reported to be
associated with iron deﬁciency [56], and this can develop
despite adequate iron supply and the absence of blood loss.
Serum hepcidin concentrations were recently studied in
obese premenopausal women [57]a n dw e r ef o u n dt ob e
in the reference range for the healthy iron-replete women.
However, when compared to lean volunteers with similar
iron deﬁciency, hepcidin levels were several-fold higher in
obese women, indicating they were inappropriately high
considering the obese women’s iron deﬁciency. Thus, in very
chronic mild inﬂammatory conditions even a mild hepcidin
excess may be suﬃcient to tip the balance between iron loss
and iron uptake and lead to iron deﬁciency.
Studies of interventions that selectively reduce hepcidin
will clarify how essential the role of hepcidin is in each type
of inﬂammation-induced anemia. In a mouse model of AI
caused by injections of Brucella abortus, hepcidin antag-
onists (neutralizing monoclonal antibody to hepcidin) in
combinationwitherythropoiesis-stimulating agentsrestored
normal hemoglobin levels [58], even when erythropoiesis-
stimulating agents alone were ineﬀective. Considering the
varietyofotherpossibleinﬂammatoryerythroidpathologies,
ranging from hemolysis to bone marrow suppression, not all
inﬂammatory conditions may respond equally to antihep-
cidin or combination therapies.
4.6. Anemia of Chronic Kidney Disease. Until recently, ane-
mia of chronic kidney disease (CKD) was thought to be
primarily due to the deﬁciency of erythropoietin. Consider-
ing that high amounts of erythropoietin are often needed to
restore erythropoiesis, this view has been challenged. This, as
well as the beneﬁcial eﬀect of high doses of intravenous iron
in CKD patients has focused attention on the possible role
of hepcidin and iron restriction in the anemia of CKD [59].
Renal excretion is a major route of hepcidin clearance. When
kidney function is normal, urinary hepcidin concentrations
correlate well with the circulating hepcidin levels, with no
apparent regulation of the excretion process. However, loss
of kidney function could decrease hepcidin clearance and
lead to the accumulation of hepcidin and the development
of iron-restrictive anemia.
Hepcidin concentrations were indeed reported to be
increased in patients with CKD [54, 60]. Although this could
be caused by inﬂammation which frequently accompanies
CKD, even patients without signiﬁcant inﬂammation had
elevated hepcidin which progressively increased with the
increasing severity of CKD [60]. Decreased kidney function
is the likely factor contributing to this phenomenon, and
some studies have reported inverse correlation between
glomerular ﬁltration rate and serum hepcidin [60, 61]. Thus,
increased hepcidin levels due to decreased renal clearance
as well as due to inﬂammation may be a signiﬁcant factor
contributing to the development of anemia in CKD and
should be considered in the development of new therapies
for this disease.
4.7. Resistance to Erythropoietin. Hyporesponsiveness to
therapeuticerythropoietinhasemergedasanimportantcon-
sequence of inﬂammation, especially in chronic kidney dis-
eases [62, 63], and may be a consequence of iron restriction
imposed by high hepcidin. As mentioned before, hepcidin-
overexpressing transgenic mice had blunted response to Epo
[4], and neutralization of hepcidin by monoclonal antibody
in the B. abortus model of AI restored responsiveness to
erythropoietin [58]. Hepcidin measurements thus may be
useful for predicting patients’ response to erythropoietin but
large studies will be necessary to test this concept.
Large pharmacological doses of Epo can sometimes
overcome the resistance of AI to erythropoietin [63]. As was
discussedbefore,Epoinjectionsinmiceandhumansresulted
in suppression of hepcidin production [29, 30], and this may
be the mechanism by which high Epo levels overcome iron
restriction. It is therefore conceivable that administration
of anti-hepcidin therapies together with erythropoiesis-
stimulating agents may improve patients’ erythropoietic
response and enable the use of lower erythropoietin doses
to avoid the potential detrimental eﬀects of high Epo
concentrations.
5. The Presentand the Futureof Hepcidin
Diagnosticsand Therapeutics inAnemias
5.1. Diagnostics. The evaluation of the diagnostic potential
of hepcidin has only recently become possible with the
development of assays for bioactive mature hepcidin in
serum and urine. The methodologies include competitive
ELISAs using biotinylated or radioiodinated hepcidin as6 Advances in Hematology
Table 1: Diagnostic and therapeutic potenital of hepcidin in diﬀerent forms of anemia.
Condition Expected hepcidin levels Other iron parameters Hepcidin therapy
Iron deﬁciency anemia Low Low Tsat and ferritin
Iron-refractory iron deﬁciency anemia High Low Tsat and ferritin Antagonist
Iron-loading anemias Low (unless transfused) High Tsat and ferritin Agonist
Anemia of inﬂammation High Low Tsat, normal-to-elevated ferritin Antagonist
Mixed anemia (AI/IDA) Normal Low Tsat, low-to-normal ferritin Antagonist
Chronic kidney disease High Variable Antagonist
Erythropoietin resistance High Variable Antagonist
Tsat = transferrin saturation.
tracers [13, 64], and several mass spectrometry-based assays
(MALDI-TOFMS,SELDI,andLC–MS/MS)usingasinternal
standardsisotopicallylabeledhepcidinortruncatedhepcidin
variants [55, 65, 66]. Measurements of prohepcidin in serum
have also been reported, but these did not correlate with
maturehepcidinconcentrationsindicatingthatpro-hepcidin
is inadequate as a substitute for measuring biologically
relevant hepcidin.
A summary of potential uses of hepcidin assays for
diagnosing diﬀerent forms of anemia is listed in Table 1.
However, the utility of hepcidin for the diagnosis and
prognosis of iron disorders is far from understood and
needs to be evaluated in larger clinical studies. Some of
the problems for interpreting hepcidin levels may include
diurnal ﬂuctuations of hepcidin (lower in the morning,
higher in the afternoon) [13, 67], and relative sensitivity to
the available iron content of the diet [13].
Hepcidin concentrations may also predict which patients
could beneﬁt from oral iron therapy. Several studies of
healthy volunteers have shown inverse correlation between
hepcidin concentrations and radiolabeled iron absorption
[68, 69]. If these results are conﬁrmed in appropriate
patient populations, patients with elevated hepcidin levels
could be treated with parenteral iron and thus avoid
weeks of potentially burdensome and unsuccessful oral iron
therapy.
5.2. Therapeutics. The potential use of hepcidin-targeted
therapeutics in anemias is summarized in Table 1. Although
no hepcidin therapies are yet available, several candidates
are currently under development. Hepcidin agonists would
be useful for preventing or ameliorating iron overload in
nontransfused β-thalassemias and other iron-loading ane-
mias. Small peptides based on hepcidin N-terminal region
have been shown to act as agonists in mice in vivo (E.
Nemeth, unpublished). The small size should allow eventual
development of orally available agonists.
Hepcidin antagonists would be expected to beneﬁt
patients with diseases of hepcidin excess (Table 1), mani-
fested as iron-restricted anemia and eventually as systemic
iron deﬁciency. Several approaches have been undertaken
to develop hepcidin antagonists. Hepcidin-neutralizing anti-
body has already been successfully used in vivo in a
mouse model of AI [58]. Apart from directly interfering
with hepcidin activity, other agents which target pathways
regulating hepcidin production have also been described.
Dorsomorphin, a small-molecule inhibitor of BMP signal-
ing, was shown to block hepcidin induction by iron in vivo
[70]. Soluble HJV, also acting as an antagonist of BMP sig-
naling, decreased hepcidin baseline expression in mice and
concurrently increased liver iron content [71]. Furthermore,
some existing therapies may be acting in part by decreasing
hepcidin production. Anticytokine therapies such as anti-
IL-6 antibody were shown to suppress hepcidin produc-
tion and improve anemia [72, 73]. Some erythropoiesis-
stimulating agents, such as prolyl hydroxylase inhibitors,
could also be eﬀective hepcidin suppressors, not only by
stimulating erythropoiesis, but also by interfering with the
HIF pathway [74]. Undoubtedly, future studies will assess
the risks and relative beneﬁts of hepcidin-targeted treatment
approaches.
6. Conclusion
Recent advances in the understanding of the key role of
hepcidin-ferroportin interaction in iron homeostasis and its
disorders have clariﬁed the pathogenesis of anemias due to
iron restriction as well as anemias accompanied by iron-
loading. While many mechanistic details of hepcidin and
ferroportin regulation remain to be worked out, we will soon
see medical applications of these advances. In the coming
years, the role of hepcidin assays in the diagnosis, prognosis,
and therapeutic stratiﬁcation of anemias will be explored.
Therapeuticinterventionsspeciﬁcallytargetingthehepcidin-
ferroportin axis for the treatment of anemias are also under
development.
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